Gengze Wu1,2, Jin Cai1, Yu Han1, Jinghai Chen2, Zhan-Peng Huang2, Caiyu Chen1, Yue Cai1, Hefei Huang1, Yujia Yang1, Yukai Liu1, Zaicheng Xu1, Duofen He1, Xiaoqun Zhang1, Xiaoyun Hu2, Luca Pinello3, Dan Zhong4, Fengtian He4, Guo-Cheng Yuan3, Da-Zhi Wang2,5, Chunyu Zeng1. 1. Department of Cardiology, Chongqing Institute of Cardiology, Daping Hospital, Third Military Medical University, Chongqing, China. 2. Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA. 3. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard School of Public Heath, Boston, MA. 4. Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Third Military Medical University, Chongqing, China. 5. Harvard Stem Cell Institute, Harvard University, Cambridge, MA.
Abstract
BACKGROUND: Long noncoding RNAs (lncRNAs) have recently been implicated in many biological processes and diseases. Atherosclerosis is a major risk factor for cardiovascular disease. However, the functional role of lncRNAs in atherosclerosis is largely unknown. METHODS AND RESULTS: We identified lincRNA-p21 as a key regulator of cell proliferation and apoptosis during atherosclerosis. The expression of lincRNA-p21 was dramatically downregulated in atherosclerotic plaques of ApoE(-/-) mice, an animal model for atherosclerosis. Through loss- and gain-of-function approaches, we showed that lincRNA-p21 represses cell proliferation and induces apoptosis in vascular smooth muscle cells and mouse mononuclear macrophage cells in vitro. Moreover, we found that inhibition of lincRNA-p21 results in neointimal hyperplasia in vivo in a carotid artery injury model. Genome-wide analysis revealed that lincRNA-p21 inhibition dysregulated many p53 targets. Furthermore, lincRNA-p21, a transcriptional target of p53, feeds back to enhance p53 transcriptional activity, at least in part, via binding to mouse double minute 2 (MDM2), an E3 ubiquitin-protein ligase. The association of lincRNA-p21 and MDM2 releases MDM2 repression of p53, enabling p53 to interact with p300 and to bind to the promoters/enhancers of its target genes. Finally, we show that lincRNA-p21 expression is decreased in patients with coronary artery disease. CONCLUSIONS: Our studies identify lincRNA-p21 as a novel regulator of cell proliferation and apoptosis and suggest that this lncRNA could serve as a therapeutic target to treat atherosclerosis and related cardiovascular disorders.
BACKGROUND: Long noncoding RNAs (lncRNAs) have recently been implicated in many biological processes and diseases. Atherosclerosis is a major risk factor for cardiovascular disease. However, the functional role of lncRNAs in atherosclerosis is largely unknown. METHODS AND RESULTS: We identified lincRNA-p21 as a key regulator of cell proliferation and apoptosis during atherosclerosis. The expression of lincRNA-p21 was dramatically downregulated in atherosclerotic plaques of ApoE(-/-) mice, an animal model for atherosclerosis. Through loss- and gain-of-function approaches, we showed that lincRNA-p21 represses cell proliferation and induces apoptosis in vascular smooth muscle cells and mouse mononuclear macrophage cells in vitro. Moreover, we found that inhibition of lincRNA-p21 results in neointimal hyperplasia in vivo in a carotid artery injury model. Genome-wide analysis revealed that lincRNA-p21 inhibition dysregulated many p53 targets. Furthermore, lincRNA-p21, a transcriptional target of p53, feeds back to enhance p53 transcriptional activity, at least in part, via binding to mouse double minute 2 (MDM2), an E3 ubiquitin-protein ligase. The association of lincRNA-p21 and MDM2 releases MDM2 repression of p53, enabling p53 to interact with p300 and to bind to the promoters/enhancers of its target genes. Finally, we show that lincRNA-p21 expression is decreased in patients with coronary artery disease. CONCLUSIONS: Our studies identify lincRNA-p21 as a novel regulator of cell proliferation and apoptosis and suggest that this lncRNA could serve as a therapeutic target to treat atherosclerosis and related cardiovascular disorders.
Authors: E Oda; R Ohki; H Murasawa; J Nemoto; T Shibue; T Yamashita; T Tokino; T Taniguchi; N Tanaka Journal: Science Date: 2000-05-12 Impact factor: 47.728
Authors: B J van Vlijmen; G Gerritsen; A L Franken; L S Boesten; M M Kockx; M J Gijbels; M P Vierboom; M van Eck; B van De Water; T J van Berkel; L M Havekes Journal: Circ Res Date: 2001-04-27 Impact factor: 17.367
Authors: Carla A Klattenhoff; Johanna C Scheuermann; Lauren E Surface; Robert K Bradley; Paul A Fields; Matthew L Steinhauser; Huiming Ding; Vincent L Butty; Lillian Torrey; Simon Haas; Ryan Abo; Mohammadsharif Tabebordbar; Richard T Lee; Christopher B Burge; Laurie A Boyer Journal: Cell Date: 2013-01-24 Impact factor: 41.582
Authors: Bing Zhang; Daniel S Day; Joshua W Ho; Lingyun Song; Jingjing Cao; Danos Christodoulou; Jonathan G Seidman; Gregory E Crawford; Peter J Park; William T Pu Journal: Genome Res Date: 2013-04-01 Impact factor: 9.043
Authors: Wolfgang Poller; Stefanie Dimmeler; Stephane Heymans; Tanja Zeller; Jan Haas; Mahir Karakas; David-Manuel Leistner; Philipp Jakob; Shinichi Nakagawa; Stefan Blankenberg; Stefan Engelhardt; Thomas Thum; Christian Weber; Benjamin Meder; Roger Hajjar; Ulf Landmesser Journal: Eur Heart J Date: 2018-08-01 Impact factor: 29.983